AHRQ clinical effectiveness research
This article was originally published in The Gray Sheet
Consolidated appropriations bill signed into law Dec. 8 provides $15 mil. to Agency for Healthcare Research & Quality for FY 2005 clinical effectiveness research - significantly less than the $50 mil. authorized by the Medicare Modernization Act for the previous fiscal year. The FY 2004 amount was never funded. AdvaMed and Guidant are among stakeholders that submitted comments on AHRQ's research agenda, which initially will focus on pharmaceuticals (1"The Gray Sheet" July 5, 2004, p. 13). Separately, on Dec. 9, AHRQ issued a Federal Register notice inviting nominations of topics for evidence reports and technology assessments. Nominations are due Jan. 31...
You may also be interested in...
AHRQ's comparative clinical effectiveness research, authorized by the Medicare Modernization Act, should invoke a broader range of data than most randomized controlled trials currently offer, AdvaMed contends
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.